|
SMT201900344T1
(it)
|
2012-09-10 |
2019-07-11 |
Principia Biopharma Inc |
Composti di pirazolopirimidina come inibitori di chinasi
|
|
PL2989106T3
(pl)
|
2013-04-25 |
2017-08-31 |
Beigene, Ltd. |
Połączone związki heterocykliczne jako inhibitory kinazy białkowej
|
|
SMT202300039T1
(it)
|
2013-09-13 |
2023-03-17 |
Beigene Switzerland Gmbh |
Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
|
|
CN112353806A
(zh)
|
2014-02-21 |
2021-02-12 |
普林斯匹亚生物制药公司 |
Btk抑制剂的盐和固体形式
|
|
TWI726608B
(zh)
|
2014-07-03 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
|
SG11201704808VA
(en)
|
2014-12-18 |
2017-07-28 |
Principia Biopharma Inc |
Treatment of pemphigus
|
|
US20180305350A1
(en)
|
2015-06-24 |
2018-10-25 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
CN109311858B
(zh)
|
2016-05-26 |
2021-12-03 |
里科瑞尔姆Ip控股有限责任公司 |
Egfr抑制剂化合物
|
|
IL263815B
(en)
|
2016-06-29 |
2022-07-01 |
Principia Biopharma Inc |
Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile
|
|
WO2018007885A1
(en)
|
2016-07-05 |
2018-01-11 |
Beigene, Ltd. |
COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
|
|
IL293319B1
(en)
|
2016-08-16 |
2026-01-01 |
Beone Medicines Ltd |
Crystal structure of s)–7–(1–acryloylpiperidin–4–yl)–2–(4–)phenoxyphenyl)–4,5,6,7–tetra–hydropyrazolo(1,5–a)pyrimidine–3–carboxamide, methods of preparation and uses thereof
|
|
CN110087680B
(zh)
|
2016-08-19 |
2024-03-19 |
百济神州有限公司 |
使用包含btk抑制剂的组合产品治疗癌症
|
|
CN106588937B
(zh)
*
|
2017-01-16 |
2018-09-21 |
东莞市真兴贝特医药技术有限公司 |
咪唑并吡嗪类化合物及其制备方法和应用
|
|
EP3573989A4
(en)
|
2017-01-25 |
2020-11-18 |
Beigene, Ltd. |
CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES
|
|
EP3645569A4
(en)
|
2017-06-26 |
2021-03-24 |
BeiGene, Ltd. |
IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
|
|
WO2019034009A1
(en)
|
2017-08-12 |
2019-02-21 |
Beigene, Ltd. |
BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY
|
|
JP6922085B2
(ja)
*
|
2017-09-28 |
2021-08-18 |
シャンハイ ハイヤン ファーマシューティカル テクノロジー カンパニー リミテッドＳｈａｎｇｈａｉ Ｈａｉｙａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． |
４，６，７−三置換 １，２−ジヒドロピロロ［３，４−ｃ］ピリジン／ピリミジン−３−オン誘導体及びその使用
|
|
US11786529B2
(en)
|
2017-11-29 |
2023-10-17 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
|
|
US11576917B2
(en)
|
2018-01-20 |
2023-02-14 |
Natco Pharma Limited |
Pharmaceutical compositions comprising Ibrutinib
|
|
KR102328682B1
(ko)
|
2018-08-27 |
2021-11-18 |
주식회사 대웅제약 |
신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
|
|
WO2020057549A1
(en)
*
|
2018-09-18 |
2020-03-26 |
Beijing Innocare Pharma Tech Co., Ltd. |
Crystalline forms of 6- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide
|
|
SG11202103861YA
(en)
*
|
2018-11-06 |
2021-05-28 |
Beijing Innocare Pharma Tech Co Ltd |
Amorphous solid dispersion comprising 6- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide
|
|
WO2020102304A1
(en)
*
|
2018-11-13 |
2020-05-22 |
Rain Therapeutics Inc. |
Combination of a kinase inhibitor and an electrolyte, compositions and methods comprising the same
|
|
ES2906316T3
(es)
*
|
2018-12-10 |
2022-04-18 |
Aphaia Ip Ag |
Formas farmacéuticas de dosificación oral para el tratamiento de trastornos metabólicos y enfermedades relacionadas mediante la liberación orquestada de enterocinas
|
|
CN109851725A
(zh)
*
|
2018-12-29 |
2019-06-07 |
华南理工大学 |
纳米纤维素-聚丙烯酰胺-明胶复合水凝胶、其制备方法及应用
|
|
EP3981399A4
(en)
|
2019-06-10 |
2023-05-31 |
BeiGene Switzerland GmbH |
ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF
|
|
AU2020328598B2
(en)
|
2019-08-15 |
2026-07-02 |
Black Diamond Therapeutics, Inc. |
Alkynyl quinazoline compounds
|
|
AU2020365951B2
(en)
|
2019-10-14 |
2026-07-16 |
Principia Biopharma Inc. |
Methods for treating immune thrombocytopenia by administering (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
|
CA3155373A1
(en)
*
|
2019-10-24 |
2021-04-29 |
Young Il Kim |
A pharmaceutical preparation comprising an amide derivative inhibiting the growth of cancer cell and a pharmaceutical product containing the same
|
|
KR102993352B1
(ko)
|
2019-12-20 |
2026-07-22 |
프린시피아 바이오파마, 인코퍼레이티드 |
2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-에네니트릴의 고체 형태
|
|
WO2021150723A1
(en)
|
2020-01-22 |
2021-07-29 |
Principia Biopharma Inc. |
Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
|
MX2023004998A
(es)
*
|
2020-11-02 |
2023-05-12 |
Black Diamond Therapeutics Inc |
Metodo para tratar canceres con derivados de quinazolina sustituida con alquino.
|
|
TN2023000295A1
(en)
*
|
2021-06-10 |
2025-07-02 |
Hikma Pharmaceuticals Usa Inc |
Oral dosage forms of ibrutinib
|
|
CN113855695B
(zh)
*
|
2021-11-01 |
2023-06-06 |
上海理工大学 |
一种结肠释药口服复方药物组合物及其制备方法
|
|
CN114181159B
(zh)
*
|
2021-12-28 |
2024-02-20 |
南通大学 |
含2,4,5-三取代嘧啶酰肼衍生物及其制备方法与应用
|
|
US11786531B1
(en)
|
2022-06-08 |
2023-10-17 |
Beigene Switzerland Gmbh |
Methods of treating B-cell proliferative disorder
|
|
CN116473923B
(zh)
*
|
2023-05-29 |
2024-05-14 |
杭州剂泰医药科技有限责任公司 |
一种奈拉替尼固体分散体组合物及其制备方法和应用
|